Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Feb. 26 — The White House Office of Management and Budget Feb. 25 began review of a proposed rule that is expected to test ways to reimburse providers for drugs administered to Medicare beneficiaries in physicians' offices and hospital outpatient departments but is likely to be opposed by provider groups.
The CMS posted a transmittal on the Part B Drug Model for its contractors that process payments, but it was subsequently removed from the agency website. The document's release was premature, according to the agency .
As described in the transmittal telling contractors about system changes, the Centers for Medicare & Medicaid Services would test different approaches for paying for Medicare Part B drugs, including cancer treatments delivered via an infusion.
Medicare pays doctors the average sales price of a Part B drug plus an additional 6 percent for treatments administered in their offices.
The transmittal that was pulled told contractors to set up a system allowing the government to vary by geographic location how much it reimburses doctors for the drugs they administer.
The current methodology “has been criticized for encouraging the use of more expensive products,” the transmittal said. It fails to account for the effectiveness of a particular drug, or the cost of comparable drugs, when determining reimbursement, it said.
However, Ted Okon, executive director of the Community Oncology Alliance, told Bloomberg BNA that the demonstration would be “a dangerous experiment that CMS wants to conduct on Medicare seniors fighting cancer.”
He said the “CMS is going to use a financial stick to force oncologists to use the drugs the government believes should be prescribed.” COA “will fight it with everything we have.”
Aaron Albright, director of the CMS's Media Relations Group, told Bloomberg BNA that the agency has been examining possible methods to “improve quality of care and increase access to affordable prescription drugs.”
Leah Ralph, director of health policy for the Association of Community Cancer Centers, told Bloomberg BNA that, if the proposal under OMB review “looks anything like the program described in the transmittal, we have very real concerns about the financial and operational impact this program would have on community oncology programs.”
She said “community oncology has seen several major changes to reimbursement” recently and centers are “having a hard time meeting the margins.”
Ralph said that, “if the details of the program prove to only put more financial pressure on providers, this is a nonstarter.”
The ACCC also is concerned about a “lack of stakeholder input in this process” and that the CMS may only allow a short comment period on the proposed regulation.
Albright said the agency expects to release more details soon.
Okon said he expects the OMB will finish review of the proposal the week of Feb. 29.
The OMB review of the Part B Drug Model (CMS-1670-P; RIN: 0938-AS85) was posted on the reginfo.gov website.
To contact the reporter on this story: Mindy Yochelson in Washington at email@example.com
To contact the editor responsible for this story: Janey Cohen at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)